Χώρα: Καναδάς
Γλώσσα: Αγγλικά
Πηγή: Health Canada
PRUCALOPRIDE (PRUCALOPRIDE SUCCINATE)
APOTEX INC
A06AX05
PRUCALOPRIDE
1MG
TABLET
PRUCALOPRIDE (PRUCALOPRIDE SUCCINATE) 1MG
ORAL
15G/50G
Prescription
MISCELLANEOUS GI DRUGS
Active ingredient group (AIG) number: 0153049001; AHFS:
APPROVED
2019-12-09
Page 1 of 37 PRODUCT MONOGRAPH PR APO-PRUCALOPRIDE Prucalopride Tablets 1 mg and 2 mg prucalopride as prucalopride succinate Prokinetic agent Apotex. Inc. Date of Preparation: 150 Signet Drive August 15, 2019 Toronto Ontario M9L 1T9 Submission Control No: 223407 Page 2 of 37 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .................................................................. 3 SUMMARY PRODUCT INFORMATION ..................................................................................... 3 INDICATIONS AND CLINICAL USE .......................................................................................... 3 CONTRAINDICATIONS ................................................................................................................ 4 WARNINGS AND PRECAUTIONS .............................................................................................. 4 ADVERSE REACTIONS ................................................................................................................ 6 DRUG INTERACTIONS .............................................................................................................. 11 DOSAGE AND ADMINISTRATION .......................................................................................... 12 OVERDOSAGE ............................................................................................................................. 13 ACTION AND CLINICAL PHARMACOLOGY ......................................................................... 13 STORAGE AND STABILITY ...................................................................................................... 16 SPECIAL HANDLING INSTRUCTIONS .................................................................................... 16 DOSAGE FORMS, COMPOSITION AND PACKAGING .......................................................... 16 PART II: SCIENTIFIC INFORMATION ......................................................................................... 18 PHARMACEUTICAL INFORMATION ................. Διαβάστε το πλήρες έγγραφο